Just 15 months after RET fusions were first identified in 1%-2% of NSCLC cases, early data from a Phase II trial of Exelixis' Cometriq suggest that blocking the target could be effective in this patient population. At least four additional investigator-initiated trials are testing marketed RET inhibitors in patients with fusion-positive lung cancer.